Flavin-containing reductase: New perspective on the detoxification of nitrobenzodiazepine

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 8, 2010, Pages 967-981

  Linwu, Shiuan Woei ^a,b,c   Wang, Andrew H J ^a,b   Peng, Fu Chuo ^d  

^a INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^b ACADEMIA SINICA   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Escherichia coli nitroreductase NfsB; Flavin containing reductase; NADPH cytochrome P450 reductase; Nitrobenzodiazepine; Rational enzyme design

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 7 AMINO 1,3 DIHYDRO 5 PHENYL 2H 1,4 BENZODIAZEPIN 2 ONE; 7 AMINOBENZODIAZEPINE; 7 AMINOFLUNITRAZEPAM; AMIODARONE; ANTIARRHYTHMIC AGENT; BENZODIAZEPINE; CLONAZEPAM; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; DRUG METABOLITE; FLAVOPROTEIN; FLUNITRAZEPAM; LITHIUM CARBONATE; MECLONAZEPAM; MENADIONE; MITOMYCIN C; NILUTAMIDE; NIMETAZEPAM; NITRAZEPAM; NITRIC OXIDE SYNTHASE; NITROBENZODIAZEPINE; NITROREDUCTASE; NORFLUNITRAZEPAM; QUINONE REDUCTASE 1; QUINONE REDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; BENZODIAZEPINE DERIVATIVE; ESCHERICHIA COLI PROTEIN; HYPNOTIC SEDATIVE AGENT; NFSB PROTEIN, E COLI; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE;

DRUG DETOXIFICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; ESCHERICHIA COLI; HUMAN; LIVER TOXICITY; LUNG TOXICITY; NEUROTOXICITY; NONHUMAN; PRESCRIPTION; REPRODUCTIVE TOXICITY; RETINOPATHY; REVIEW; ANIMAL; CHEMISTRY; ENZYMOLOGY; METABOLISM; STRUCTURE ACTIVITY RELATION; TOXICITY;

ANIMALS; BENZODIAZEPINES; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLAVOPROTEINS; HUMANS; HYPNOTICS AND SEDATIVES; NADPH-FERRIHEMOPROTEIN REDUCTASE; NITROREDUCTASES; QUINONES; STRUCTURE-ACTIVITY RELATIONSHIP;

ESCHERICHIA COLI;

EID: 77954841657     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.482928     Document Type: Review

References (117)

1. Childress SJ, Gluckman MI. 1,4-Benzodiazepines. J Pharm Sci 1964;53:577-590
2. Haefely WE. Central actions of benzodiazepines: general introduction. Br J Psychiatry 1978;133:231-238
3. Loew GH, Nienow JR, Poulsen M. Theoretical structure-activity studies of benzodiazepine analogues. Requirements for receptor affinity and activity. Mol Pharmacol 1984;26(1):19-34
4. Shader RI, Greenblatt DJ. Benzodiazepines: some aspects of their clinical pharmacology. Ciba Found Symp 1979;(74):141-155
5. Robertson MD, Drummer OH. Postmortem distribution and redistribution of nitrobenzodiazepines in man. J Forensic Sci 1998;43(1):9-13
6. Mizuno K, Katoh M, Okumura H, et al. Metabolic activation of benzodiazepines by CYP3A4. Drug Metab Dispos 2009;37(2):345-351
7. Darragh A, Lambe R, Brick I, et al. Antagonism of the central effects of 3-methylclonazepam. Br J Clin Pharmacol 1982;14(6):871-872
8. Amir L, Waisman Y. Medical and toxicological aspects of drug facilitated sexual assault. Isr J Emerg Med 2006;6(3):62-66
9. Gambi F, Conti CM, Grimaldi MR, et al. Flunitrazepam a benzodiazepine most used among drug abusers. Int J Immunopathol Pharmacol 1999;12(3):157-159
10. Lane SD, Cherek DR, Nouvion SO. Modulation of human risky decision making by flunitrazepam. Psychopharmacology (Berl) 2008;196(2):177-188
11. Pirnay S, Megarbane B, Decleves X, et al. Buprenorphine alters desmethylflunitrazepam disposition and flunitrazepam toxicity in rats. Toxicol Sci 2008;106(1):64-73
12. Kilicarslan T, Haining RL, Rettie AE, et al. Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metab Dispos 2001;29(4 Pt 1):460-465
13. Hesse LM, Venkatakrishnan K, von Moltke LL, et al. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos 2001;29(2):133-140 (Pubitemid 32112926)
14. Saito H, Kobayashi H, Takeno S, et al. In vivo and in vitro studies on fetal toxicity of benzodiazepines in rats. Res Commun Chem Pathol Pharmacol 1986;52(3):295-304
15. De Silva JA, Puglisi CV, Munno N. Determination of clonazepam and flunitrazepam in blood and urine by electron-capture GLC. J Pharm Sci 1974;63(4):520-527
16. Ask K, Decologne N, Asare N, et al. Distribution of nitroreductive activity toward nilutamide in rat. Toxicol Appl Pharmacol 2004;201(1):1-9
17. Peterson FJ, Mason RP, Hovsepian J, et al. Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J Biol Chem 1979;254(10):4009-4014
18. Takeno S, Sakai T. Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction. Teratology 1991;44(2):209-214
19. Robertson MD, Drummer OH. Postmortem drug metabolism by bacteria. J Forensic Sci 1995;40(3):382-386
20. Wilson WR, Hicks KO, Pullen SM, et al. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 2007;167(6):625-636
21. Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004;56(1):53-102
22. Sarlauskas J, Nemeikaite-Ceniene A, Anusevicius Z, et al. Flavoenzyme-catalyzed redox cycling of hydroxylamino- and amino metabolites of 2,4,6-trinitrotoluene: implications for their cytotoxicity. Arch Biochem Biophys 2004;425(2):184-192
23. Anlezark GM, Melton RG, Sherwood RF, et al. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1992;44(12):2289-2295
24. Fukinaga M, Ishizawa K, Kamei C. Anticonvulsant properties of 1,4-benzodiazepine derivatives in amygdaloid-kindled seizures and their chemical structure-related anticonvulsant action. Pharmacology 1998;57(5):233-241
25. Bogusz MJ, Maier RD, Kruger KD, et al. Determination of flunitrazepam and its metabolites in blood by high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 1998;713(2):361-369
26. Druid H, Holmgren P, Ahlner J. Flunitrazepam: an evaluation of use, abuse and toxicity. Forensic Sci Int 2001;122(2-3):136-141
27. Berthault F, Kintz P, Mangin P. Simultaneous high-performance liquid chromatographic analysis of flunitrazepam and four metabolites in serum. J Chromatogr B Biomed Appl 1996;685(2):383-387
28. Poisnel G, Dhilly M, Le Boisselier R, et al. Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci 2009;110(1):36-46
29. Drummer OH, Syrjanen ML, Cordner SM. Deaths involving the benzodiazepine flunitrazepam. Am J Forensic Med Pathol 1993;14(3):238-243
30. Browne TR. Clonazepam. A review of a new anticonvulsant drug. Arch Neurol 1976;33(5):326-332
31. Lorizio A. Treatment of the epilepsy using clonazepam (RO 5-4023 - Rivotril). Riv Neurobiol 1972;18(3-4):233-240
32. Negrusz A, Bowen AM, Moore CM, et al. Deposition of 7-aminoclonazepam and clonazepam in hair following a single dose of Klonopin. J Anal Toxicol 2002;26(7):471-478
33. Gatzonis S, Karadimas P, Gatzonis S, et al. Clonazepam associated retinopathy. Eur J Ophthalmol 2003;13(9-10):813-815
34. Koczerginski D, Kennedy SH, Swinson RP. Clonazepam and lithium-a toxic combination in the treatment of mania? Int Clin Psychopharmacol 1989;4(3):195-199
35. Witt DM, Ellsworth AJ, Leversee JH. Amiodarone-clonazepam interaction. Ann Pharmacother 1993;27(12):1463-1464
36. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann NY Acad Sci 2003;993:103-14; discussion 23-24
37. Eschenhof E. Studies on the disposition of the anticonvulsant clonazepam in the organisms of rat, dog, and man. Arzneimittelforschung 1973;23(3):390-400
38. Sjo O, Hvidberg EF, Naestoft J, et al. Pharmacokinetics and side-effects of clonazepam and its 7-amino-metabolite in man. Eur J Clin Pharmacol 1975;8(3-4):249-254
39. Ansseau M, Doumont A, Thiry D, et al. Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design. Psychopharmacology (Berl) 1985;87(2):130-135
40. Thibaut JP, Monteiro LM, Leite LC, et al. The effects of 3-methylclonazepam on Schistosoma mansoni musculature are not mediated by benzodiazepine receptors. Eur J Pharmacol 2009;606(1-3):9-16
41. O'Boyle C, Lambe R, Darragh A. Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam. Eur J Clin Pharmacol 1985;29(1):105-108
42. Davies C, Levine S. A controlled comparison of nitrazepam ('mogadon') with sodium amylobarbitone as a sleep-inducing agent. Br J Psychiatry 1967;113(502):1005-1008
43. Berman AJ, Pomina AC, Nepomuceno NR. Anticonvulsant properties of nitrazepam (mogadon). Electroencephalogr Clin Neurophysiol 1968;24(2):187
44. Giri AK, Banerjee S. Genetic toxicology of four commonly used benzodiazepines: a review. Mutat Res 1996;340(2-3):93-108
45. Takeno S, Hirano Y, Kitamura A, et al. Comparative developmental toxicity and metabolism of nitrazepam in rats and mice. Toxicol Appl Pharmacol 1993;121(2):233-238
46. Kishi K, Kanamori S, Maruyama T, et al. Potential parameters of male reproductive toxicity: reproductive performance, histopathology and sperm evaluation in SD rats given nitrazepam. J Toxicol Sci 1995;20(3):329-339
47. Saito H, Kobayashi H, Takeno S, et al. Fetal toxicity of benzodiazepines in rats. Res Commun Chem Pathol Pharmacol 1984;46(3):437-447
48. Yanagi Y, Haga F, Endo M, et al. Comparative metabolic study of nimetazepam and its desmethyl derivative (nitrazepam) in rats. Xenobiotica 1975;5(4):245-247
49. Kuang H, Li Q, Shen C, et al. A highly sensitive method for the determination of 7-aminonitrazepam, a metabolite of nitrazepam, in human urine using high-performance electrospray liquid chromatography tandem mass spectrometry. Biomed Chromatogr 2009;23(7):740-744
50. Kangas L. Determination of nitrazepam and its main metabolites in urine by gas-liquid chromatography: use of electron capture and nitrogen-selective detectors. J Chromatogr 1979;172:273-278
51. Yanagi Y, Haga F, Endo M, et al. Comparative metabolic study of nimetazepam and its desmethyl derivative (nitrazepam) in dogs. Xenobiotica 1976;6(2):101-112
52. Sumirtapura YC, Aubert C, Coassolo P, et al. Determination of 7-amino-flunitrazepam (Ro 20-1815) and 7-amino-desmethylflunitrazepam (Ro 5-4650) in plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr 1982;232(1):111-118
53. Petters I, Peng DR, Rane A. Quantitation of clonazepam and its 7-amino and 7-acetamido metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1984;306:241-248
54. Elmer GW, Remmel RP. Role of the intestinal microflora in clonazepam metabolism in the rat. Xenobiotica 1984;14(11):829-840
55. Jonen HG. Enhancement of reductive metabolism of p-nitrobenzoate and nitrazepam in isolated perfused rat liver by ethanol. Drug Metab Dispos 1979;7(3):176-180
56. Hewick DS, Shaw V. The importance of the intestinal microflora in nitrazepam metabolism in the rat [proceedings]. Br J Pharmacol 1978;62(3):427P
57. Seree EJ, Pisano PJ, Placidi M, et al. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol 1993;7(2):69-75
58. Berson A, Wolf C, Berger V, et al. Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide. J Pharmacol Exp Ther 1991;257(2):714-719
59. Peng FC, Chaing HH, Tang SH, et al. NADPH-cytochrome P-450 reductase is involved in flunitrazepam reductive metabolism in Hep G2 and Hep 3B cells. J Toxicol Environ Health A 2004;67(2):109-124
60. Leclerc H, Mossel DA, Edberg SC, et al. Advances in the bacteriology of the coliform group: their suitability as markers of microbial water safety. Annu Rev Microbiol 2001;55:201-234
61. Roldan MD, Perez-Reinado E, Castillo F, et al. Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev 2008;32(3):474-500
62. Rau J, Stolz A. Oxygen-insensitive nitroreductases NfsA and NfsB of Escherichia coli function under anaerobic conditions as lawsone-dependent Azo reductases. Appl Environ Microbiol 2003;69(6):3448-3455
63. Liochev SI, Hausladen A, Fridovich I. Nitroreductase A is regulated as a member of the soxRS regulon of Escherichia coli. Proc Natl Acad Sci USA 1999;96(7):3537-3539 (Pubitemid 29168944)
64. Patel P, Young JG, Mautner V, et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther 2009;17(7):1292-1299
65. LinWu SW, Syu CJ, Chen YL, et al. Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines. Biochem Pharmacol 2009;78(1):96-103
66. Kaplan SA, Alexander K, Jack ML, et al. Pharmacokinetic profiles of clonazepam in dog and humans and of flunitrazepam in dog. J Pharm Sci 1974;63(4):527-532
67. Moriya F, Hashimoto Y. Tissue distribution of nitrazepam and 7-aminonitrazepam in a case of nitrazepam intoxication. Forensic Sci Int 2003;131(2-3):108-112
68. Moreno SN, Mason RP, Docampo R. Reduction of nifurtimox and nitrofurantoin to free radical metabolites by rat liver mitochondria. Evidence of an outer membrane-located nitroreductase. J Biol Chem 1984;259(10):6298-6305
69. Mason RP, Holtzman JL. The mechanism of microsomal and mitochondrial nitroreductase. Electron spin resonance evidence for nitroaromatic free radical intermediates. Biochemistry 1975;14(8):1626-1632
70. Abou-Khalil S, Abou-Khalil WH, Yunis AA. Identification of a mitochondrial p-dinitrobenzene reductase activity in rat liver. Pharmacology 1985;31(6):301-308
71. Bartosek I, Mussini E, Saronio C, et al. Studies on nitrazepam reduction in vitro. Eur J Pharmacol 1970;11(2):249-253
72. Koder RL, Haynes CA, Rodgers ME, et al. Flavin thermodynamics explain the oxygen insensitivity of enteric nitroreductases. Biochemistry 2002;41(48):14197-14205
73. Smyth GE, Orsi BA. Nitroreductase activity of NADH dehydrogenase of the respiratory redox chain. Biochem J 1989;257(3):859-863
74. Ghafourifar P, Cadenas E. Mitochondrial nitric oxide synthase. Trends Pharmacol Sci 2005;26(4):190-195
75. Ghafourifar P, Richter C. Nitric oxide synthase activity in mitochondria. FEBS Lett 1997;418(3):291-296
76. Stuehr DJ, Tejero J, Haque MM. Structural and mechanistic aspects of flavoproteins: electron transfer through the nitric oxide synthase flavoprotein domain. FEBS J 2009;276(15):3959-3974
77. Chandor A, Dijols S, Ramassamy B, et al. Metabolic activation of the antitumor drug 5-(Aziridin-1-yl)- 2,4-dinitrobenzamide (CB1954) by NO synthases. Chem Res Toxicol 2008;21(4):836-843
78. Ask K, Dijols S, Giroud C, et al. Reduction of nilutamide by NO synthases: implications for the adverse effects of this nitroaromatic antiandrogen drug. Chem Res Toxicol 2003;16(12):1547-1554
79. Vella F, Ferry G, Delagrange P, et al. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol 2005;71(1-2):1-12
80. Bianchet MA, Erdemli SB, Amzel LM. Structure, function, and mechanism of cytosolic quinone reductases. Vitam Horm 2008;78:63-84
81. Graves PR, Kwiek JJ, Fadden P, et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol 2002;62(6):1364-1372
82. Dinkova-Kostova AT, Talalay P. Persuasive evidence that quinone reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. Free Radic Biol Med 2000;29(3-4):231-240
83. Knox RJ, Jenkins TC, Hobbs SM, et al. Bioactivation of 5-(aziridin-1-yl)- 2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res 2000;60(15):4179-4186
84. Jamieson D, Tung AT, Knox RJ, et al. Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor. Br J Cancer 2006;95(9):1229-1233
85. Knox RJ, Boland MP, Friedlos F, et al. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)- 2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2- nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 1988;37(24):4671-4677
86. Choi JW, Lee J, Nishi K, et al. Crystal structure of a minimal nitroreductase, ydjA, from Escherichia coli K12 with and without FMN cofactor. J Mol Biol 2008;377(1):258-267
87. Barak Y, Thorne SH, Ackerley DF, et al. New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution. Mol Cancer Ther 2006;5(1):97-103
88. Zhao Q, Modi S, Smith G, et al. Crystal structure of the FMN-binding domain of human cytochrome P450 reductase at 1.93 A resolution. Protein Sci 1999;8(2):298-306
89. Xia C, Misra I, Iyanagi T, Kim JJ. Regulation of interdomain interactions by calmodulin in inducible nitric oxide synthase. J Biol Chem 2009;284(44):30708-30717
90. Skelly JV, Sanderson MR, Suter DA, et al. Crystal structure of human DT-diaphorase: a model for interaction with the cytotoxic prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). J Med Chem 1999;42(21):4325- 4330
91. Parkinson GN, Skelly JV, Neidle S. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J Med Chem 2000;43(20):3624-3631
92. Kobori T, Sasaki H, Lee WC, et al. Structure and site-directed mutagenesis of a flavoprotein from Escherichia coli that reduces nitrocompounds: alteration of pyridine nucleotide binding by a single amino acid substitution. J Biol Chem 2001;276(4):2816-2823
93. Holm L, Kaariainen S, Rosenstrom P, et al. Searching protein structure databases with DaliLite v.3. Bioinformatics 2008;24(23):2780-2781
94. Kolbeck B, May P, Schmidt-Goenner T, et al. Connectivity independent protein-structure alignment: a hierarchical approach. BMC Bioinformatics 2006;7:510
95. Vass SO, Jarrom D, Wilson WR, et al. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954. Br J Cancer 2009;100(12):1903-1911
96. Amrein R, Leishman B, Bentzinger C, et al. Flumazenil in benzodiazepine antagonism. Actions and clinical use in intoxications and anaesthesiology. Med Toxicol Adverse Drug Exp 1987;2(6):411-429
97. Emptage CD, Knox RJ, Danson MJ, et al. Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation. Biochem Pharmacol 2009;77(1):21-29
98. Gao D, Narasimhan DL, Macdonald J, et al. Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol 2009;75(2):318-323
99. Singlas E. Pharmacokinetics of flunitrazepam. Nouv Presse Med 1979;8(31):2519-2523
100. Hall PM, Stupans I, Burgess W, et al. Immunohistochemical localization of NADPH-cytochrome P450 reductase in human tissues. Carcinogenesis 1989;10(3):521-530 (Pubitemid 19089919)
101. Pan SS, Andrews PA, Glover CJ, et al. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 1984;259(2):959-966
102. Chat M, Bayol-Denizot C, Suleman G, et al. Drug metabolizing enzyme activities and superoxide formation in primary and immortalized rat brain endothelial cells. Life Sci 1998;62(2):151-163
103. Schmalix WA, Lang D, Schneider A, et al. Stable expression and coexpression of human cytochrome P450 oxidoreductase and cytochrome P450 1A2 in V79 Chinese hamster cells: sensitivity to quinones and biotransformation of 7-alkoxyresorufins and triazines. Drug Metab Dispos 1996;24(12):1314-1319
104. Berger V, Berson A, Wolf C, et al. Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol 1992;43(3):654-657
105. Navarro A, Boveris A. Mitochondrial nitric oxide synthase, mitochondrial brain dysfunction in aging, and mitochondria-targeted antioxidants. Adv Drug Deliv Rev 2008;60(13-14):1534-1544
106. Garner AP, Paine MJ, Rodriguez-Crespo I, et al. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res 1999;59(8):1929-1934
107. Jiang HB, Ichikawa M, Furukawa A, et al. Reductive activation of mitomycin C by neuronal nitric oxide synthase. Biochem Pharmacol 2000;60(4):571-579
108. Kobzik L, Bredt DS, Lowenstein CJ, et al. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 1993;9(4):371-377
109. Bachmann S, Bosse HM, Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol 1995;268(5 Pt 2):F885-98
110. Pou S, Pou WS, Bredt DS, et al. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 1992;267(34):24173-24176
111. Geller DA, Lowenstein CJ, Shapiro RA, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA 1993;90(8):3491-3495
112. Terenghi G, Riveros-Moreno V, Hudson LD, et al. Immunohistochemistry of nitric oxide synthase demonstrates immunoreactive neurons in spinal cord and dorsal root ganglia of man and rat. J Neurol Sci 1993;118(1):34-37
113. Lowenstein CJ, Glatt CS, Bredt DS, et al. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc Natl Acad Sci USA 1992;89(15):6711-6715
114. Ozuyaman B, Grau M, Kelm M, et al. RBC NOS: regulatory mechanisms and therapeutic aspects. Trends Mol Med 2008;14(7):314-322
115. Joseph P, Long DJ, 2nd, et al. Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. Biochem Pharmacol 2000;60(2):207-214
116. Liao S, Dulaney JT, Williams-Ashman HG. Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide. J Biol Chem 1962;237:2981-2987
117. Zenno S, Koike H, Kumar AN, et al. Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J Bacteriol 1996;178(15):4508-4514